Skip to content

Effects of Memantine on the incidence of Delirium

Effects of Memantine on the incidence of Delirium in patients undergoing open heart surgery

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016061324236N2
Enrollment
60
Registered
2016-06-19
Start date
2014-12-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium. Postoperative Delirium

Interventions

Intervention 1: The intervention group: 14 Memantin tablets 10 miligram for the twice-daily use for a week from three days before surgery to three days then. Intervention 2: Control group:14 tablets
Treatment - Drugs
The intervention group: 14 Memantin tablets 10 miligram for the twice-daily use for a week from three days before surgery to three days then
Control group:14 tablets of Memantine placebo for the twice-daily use for a week from three days before surgery to three days then

Sponsors

Vice chancellor for research Yazd Shahid Sadoughi University of medical sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients aged 50 to 70 years, Signing the informed consent form. Exclusion criteria: EF (ejection fraction) of less than 35%, alcohol and drug abuse, pregnancy and lactation, brain damage, kidney failure (creatinine greater than 1.4), liver failure, scores of MMSE (Mini-Mental State Examination) less than 22? concurrent use of Cholinesterase inhibitors.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Delirium. Timepoint: 3 days after operation. Method of measurement: Questionnaire of CAM-ICU.

Secondary

MeasureTime frame
Drug side effects. Timepoint: 3 days after operation. Method of measurement: Examination and test results.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Houshang Mehrparvar

Yazd Shahid Sadoughi university of medical sciences

ahmehrparvar@ssu.ac.ir+98 35 3726 3733

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026